About Event
This summit was a unique opportunity to connect with over 70 specialists in Upstream & Downstream Process Development, Analytical Development, CMC, Manufacturing, and Drug Product at the 3rd mRNA Process Development & Manufacturing Summit Europe to drive innovation, establish key frameworks, and forge partnerships that tackle process, scale, and regulatory hurdles, ensuring the mRNA industry can continue to supercharge safe and effective mRNA drugs from research into the clinic and beyond.
What You Missed in 2025
Interactive Regulatory Panel Discussion
➜ Kickstarting Day One by joining leading regulatory experts to address burning questions on the evolving approval landscape for mRNA therapeutics and vaccines.
➜ Gaining exclusive insights into the latest guidelines and end-to-end strategies to streamline regulatory pathways, ensuring faster and smoother product approvals.
Pioneering Advances in Biotech
➜ Learning from pioneering biotechs Ceva, Altamira and Divincells, who discussed next-gen formulations, both liquid & freeze dried, stabilisation techniques and advanced purification processes, to optimise efficiency in scalable and cost-effective production, for reducing the time from lab to market.
New Companies on the Agenda in 2025
Refreshed Speaker Faculty Including:
Hot Sessions for 2025:
Harnessing the use of Synthetic DNA and mRNA to shorten end-to-end production timelines, reduce waste and improve cost efficiency, ensuring regulatory compliance for safer and more effective mRNA therapeutics and vaccines with expertise from CureVac and Genevation
Detecting deviations instantly and troubleshoot bottlenecks in real time by leveraging real-time process monitoring techniques to produce high quality mRNA drugs consistently. Shifting from offline to in-line analytical techniques with University of Sheffield
Implementing stabilisation techniques that extend shelf life and bridge the gap towards room temperature storage, reducing logistical challenges and increasing accessibility for patients with Ethris and Divincell
With LNPs as the gold standard for mRNA formulation during the pandemic, leveraging crucial insights into nextgen formulations including freeze, dried, liquid and non lipid based to enhance applications across a wider range of therapeutic areas with Altamira Tx
Joining CEPI and BioNTech to ensure GMP compliance and achieve seamless scalability from small-batch personalised therapies to high volume production, meeting growing market demands while maintaining cost-efficiency